BridgeBio Pharma Inc.

NASDAQ: BBIO · Real-Time Price · USD
51.56
0.38 (0.74%)
At close: Aug 15, 2025, 12:48 PM

BridgeBio Pharma Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
221.9M 9.3M 77.65M 69.72M
Cost of Revenue
3.88M 2.45M 3.43M 3.11M
Gross Profit
218.02M 6.86M 74.21M 66.6M
Operating Income
-592.97M -607.37M -471.87M -579.75M
Interest Income
17.25M 18.04M 7.54M 1.13M
Pretax Income
-542.19M -653.25M -484.65M -586.45M
Net Income
-535.76M -643.2M -493.96M -639.3M
Selling & General & Admin
288.93M 150.59M 143.19M 192.21M
Research & Development
506.46M 455.71M 402.9M 454.14M
Other Expenses
15.61M 7.93M n/a n/a
Operating Expenses
811M 614.23M 546.09M 646.35M
Interest Expense
99.29M 81.29M 80.44M 46.78M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
814.88M 616.67M 546.09M 646.35M
Income Tax Expense
1.15M n/a 9.31M 52.84M
Shares Outstanding (Basic)
186.08M 162.79M 147.47M 144.36M
Shares Outstanding (Diluted)
186.08M 162.79M 147.47M 144.36M
EPS (Basic)
-2.88 -3.95 -3.35 -4.43
EPS (Diluted)
-2.88 -3.95 -3.35 -4.43
EBITDA
-436.83M -565.47M -397.44M -533.83M
EBIT
-442.9M -571.96M -404.21M -539.68M
Depreciation & Amortization
6.08M 6.49M 6.77M 5.84M